Lung Cancer

Almost two-thirds of thoracic oncologists used telehealth for the first time during the COVID-19 pandemic, according to survey results presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Nivolumab plus ipilimumab conferred a durable survival benefit compared with chemotherapy as first-line treatment for unresectable malignant pleural mesothelioma, according to randomized phase 3 trial data released by the manufacturer.

Use of atezolizumab as part of neoadjuvant therapy and again as maintenance met predetermined safety criteria for patients with resectable pleural mesothelioma, according to study results.

Considerably fewer community oncology clinicians than academic clinicians use biomarker testing to guide discussions with patients with lung cancer, according to survey results.

In the spring of 2019, Heather A. Wakelee, MD, was approached by a group of young women seeking guidance and connection in their careers as thoracic oncologists.

The combination of atezolizumab, carboplatin and pemetrexed demonstrated encouraging activity among patients with nonsquamous non-small cell lung cancer and untreated, asymptomatic brain metastases, according to phase 2 study results.

Adjuvant atezolizumab improved DFS among patients with non-small cell lung cancer with nodal involvement, according to study results.

Lurbinectedin plus doxorubicin did not improve OS among patients with small cell lung cancer, according to results of the randomized phase 3 ATLANTIS trial.

The addition of nivolumab and ipilimumab to first-line chemotherapy conferred durable survival benefits to patients with advanced non-small cell lung cancer and brain metastases, according to results of the phase 3 CheckMate 9LA trial.

Enrollment in lung cancer clinical trials declined by more than 40% amid the COVID-19 pandemic, according to results of a global survey presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.